Systemic inflammation leading to neuroinflammation is a matter of concern in recent years because of its implication with neurological disorders. Selective peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists have shown promising anti-inflammatory effects in various neurodegenerative diseases. With pioglitazone being one such PPAR-γ agonist, our study was aimed at investigating the role of pioglitazone on oxidative stress and cognitive changes against LPS-induced neuroinflammation in rats. In-house-bred male Wistar rats, about six weeks old, were utilized for the present study. They were categorized as A (preventive) and B (curative) groups, each with five subgroups: control (1A and 1B), neuro-inflammatory (2A and 2B), and three different dosages of pioglitazone treatment (3A, 3B, 4A, 4B, and 5A, 5B). After the experimental period, cognitive changes were examined by behavioral tests. Brain homogenate was used for biochemical parameters. Deteriorated memory, superoxide dismutase activity and increase in lipid peroxidation in the brain tissue induced by LPS exposure were substantially alleviated (p < 0.001) by pioglitazone treatment. These results suggest that pioglitazone may be neuroprotective against LPS-induced neuroinflammation.
Blossom et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: